BioSpace News Archive

Following 12 years of pioneering research activities, Oncomatryx is embarking on a new phase in the development of its tumor microenvironment - targeted ADCs.

Preclinical imaging is the most vital step in the research of living animals and drug development.

Paradigm Biopharmaceuticals, a global biopharmaceutical company specializing in repurposing existing drugs for unmet medical needs, announced their retention of Rubenstein Public Relations as its agency of record.

Endpoint Health, Inc., today announced new retrospective analyses that provide additional insights into the company’s artificial intelligence-driven approach to identifying biologically-distinct groups within diseases predictive of outcomes of different treatment strategies in adults with acute respiratory distress syndrome (ARDS).

Trauma devices are one of the different clinical strategies utilized for the treatment of injury in view of the seriousness of injury.

Breckenridge Pharmaceutical, Inc. announces that it has launched Lacosamide Tablets, USP (generic version of Vimpat®).

Newtopia Inc. today announced that Jeff Ruby , Founder and CEO, will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place at the Metro Toronto Convention Centre, North Building on May 2nd and 3rd, 2022.

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its first quarter 2022 financial results after market close on May 4th, 2022.

Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) will be presenting at the Bloom Burton & Co. Healthcare Investor Conference from May 2 to 3, 2022.

Waters Corporation (NYSE:WAT) announced today that it will host its 2022 Investor Day on Thursday, May 19, 2022, starting at 8:45 a.m. (ET) at the New York Stock Exchange, 11 Wall St, New York, NY 10005.